behalf

NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.

Source Node:
Time Stamp: October 24, 2023 11:54 AM - Modified On: October 24, 2023 - Published By:
Source Cluster:
Republished By Plato

Summary: Progress in Neurodegenerative Research:  NKGen’s Phase 1/2a Clinical Trial for SNK01 on Track for End-of-Year Initiation SANTA ANA, Calif., Oct. 24, 2023 (Plato / Amplifi) -- Today, NKGen Biotech Inc. (Nasdaq: NKGN), a trailblazer in the field of autologous, allogeneic, and CAR-NK natural killer cell therapeutics, proudly announced the progression of its SNK01 program targeting Alzheimer’s Disease (AD), backed by the green light from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application. NKGen is gearing up to initiate its Phase 1/2a clinical trial

The GBA Recognizes Blockchain Trailblazers

Source Node:
Time Stamp: June 4, 2023 4:13 PM - Modified On: June 4, 2023 - Published By:
Source Cluster:
Republished By Plato

Washington, DC, June 4 2023 – The Government Blockchain Association (GBA) honored exceptional individuals and organizations for their groundbreaking use of blockchain technology in solving public sector challenges. The Annual Achievement Awards, presented on May 24, 2023, in Washington, DC, celebrated this year's outstanding winners. Rosemarie McClean, Chief Executive Officer, and Dino Cataldo Dell’Accio, Chief Information Officer received the award on behalf of the United Nations Joint Staff Pension Fund (UNJSPF), the Organization Award for a digital identity solution that enabled over 23,000 retirees across 180 countries, to provide their